23 research outputs found

    Decoupling in an expanding universe: boundary RG-flow affects initial conditions for inflation

    Full text link
    We study decoupling in FRW spacetimes, emphasizing a Lagrangian description throughout. To account for the vacuum choice ambiguity in cosmological settings, we introduce an arbitrary boundary action representing the initial conditions. RG flow in these spacetimes naturally affects the boundary interactions. As a consequence the boundary conditions are sensitive to high-energy physics through irrelevant terms in the boundary action. Using scalar field theory as an example, we derive the leading dimension four irrelevant boundary operators. We discuss how the known vacuum choices, e.g. the Bunch-Davies vacuum, appear in the Lagrangian description and square with decoupling. For all choices of boundary conditions encoded by relevant boundary operators, of which the known ones are a subset, backreaction is under control. All, moreover, will generically feel the influence of high-energy physics through irrelevant (dimension four) boundary corrections. Having established a coherent effective field theory framework including the vacuum choice ambiguity, we derive an explicit expression for the power spectrum of inflationary density perturbations including the leading high energy corrections. In accordance with the dimensionality of the leading irrelevant operators, the effect of high energy physics is linearly proportional to the Hubble radius H and the scale of new physics L= 1/M.Comment: LaTeX plus axodraw figures. v2: minor corrections; refs added. JHEP style: 34 pages + 18 pages appendi

    In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

    Get PDF
    Comment in Lowering the High Cost of Cancer Drugs--III. [Mayo Clin Proc. 2016] Lowering the High Cost of Cancer Drugs--I. [Mayo Clin Proc. 2016] Lowering the High Cost of Cancer Drugs--IV. [Mayo Clin Proc. 2016] In Reply--Lowering the High Cost of Cancer Drugs. [Mayo Clin Proc. 2016] US oncologists call for government regulation to curb drug price rises. [BMJ. 2015
    corecore